Department of Health 
and
Human Services' logo Department of Health and Human Services

Public Health Service
Food and Drug Administration

 

Atlanta District Office
60 Eighth Street, NE
Atlanta, GA 30309

VIA FEDERAL EXPRESS

November 6, 2003

Bjarte Rene
Owner/President
American Nutraceuticals Company
3340 Peachtree Rd., Suite 1110
Atlanta, GA 30326

Warning Letter
(04-ATL-01)

Dear Mr. Rene:

On July 1, 2003, FDA investigators Leah M. Andrews and Jacqueline D. Mitchell inspected your firm’s facility. During the investigation, our investigators collected a list of products distributed by your firm and samples of all available labels and promotional materials for products marketed and distributed by your firm. As a result of our investigation and review of these labels and promotional materials, we have determined that a number of your products fail to comply with provisions of the Federal Food, Drug and Cosmetic Act (the Act).

Under Section 201(g)(1)(B) of the Act (21 U.S.C. 321(g)(1)(B)), articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease are drugs. The following claims on your products’ labels and promotional materials indicate that these products are intended to be used as drugs:

These claims cause the products to be drugs as defined in Section 201(g)(1)(B) of the Act (21 U.S.C. 3 321(g)(1)(B)). Because the products are not generally recognized as safe and effective when used as labeled, they are also new drugs as defined in Section 201(p) of the Act (21 U.S.C. 321 (p)). New drugs may not be legally marketed in the United States without prior approval from FDA as described in Section 505(a) of the Act (21 U.S.C. 355(a)). Furthermore, the products are also misbranded under Section 502(f)(1) of the Act (21 U.S.C. 352(f)(1)) because their labeling fails to bear adequate directions for use for the conditions for which they are offered.

Under the Act, labeling for a dietary supplement may include claims that, among others, describe the role of a nutrient or dietary ingredient intended to affect the structure or function in humans, or characterize the documented mechanism by which a dietary ingredient acts to maintain such structure or function (see 21 U.S.C. 343(r)(6)(A)). However, these “structure/function” claims must be truthful and not misleading (see 21 U.S.C. 343(a)(1), 343(r)(6)(B)). Upon review of the labeling, including promotional materials, for some of your products, we have determined that they include the following structure/function claims:

We have reviewed these claims and have concluded that they are not supported by reliable scientific evidence. Because these claims lack substantiation, they cause your products to be misbranded within the meaning of Sections 403(a)(1) and 403(r)(6) of the Act (21 U.S.C. 343(a)(1) and 343(r)(6)).

This letter is not intended to be an all inclusive review of all labeling and products your firm markets. It is your responsibility to ensure that all products marketed by your firm are in compliance with the Act and its implementing regulations.

We request that you take prompt action to correct these violations. Failure to promptly correct these violations may result in enforcement action without further notice. The Federal Food, Drug and Cosmetic Act provides for the seizure of illegal products and for injunction against the manufacturer and/or distributor of illegal products.

In addition, during the inspection, the investigators noted that you also distribute topical cream products, some of which may be subject to OTC drug monographs. You should review your products to ensure that they meet all applicable regulatory requirements, including the requirements of any applicable monographs.

Please notify this office in writing within fifteen (15) working days of receipt of this letter as to the specific steps you have taken to correct the stated violations. You should also include an explanation of each step being taken to identify and make corrections to ensure that similar violations will not recur. If corrective action cannot be completed within 15 working days, state the reason for the delay and the time within which the corrections will be implemented.

Your reply should be directed to the attention of Serene N. Ackall, Compliance Officer, at the address noted in the letterhead. Ms. Ackall can be reached at 404-253-1296 to discuss the content of this letter or any questions you have about the promotion of your other products.

Sincerely,
/s/
Mary Woleske, Director
Atlanta District

This page was posted on July 9, 2005.

Links to Recommended Companies